Stock·NYSE·Healthcare
Zoetis Inc. (ZTS)
- Market cap
- $32.80B
- P/E
- 12.74
- Dividend yield
- 2.63%
- Street target
- $89.50median of 17 analysts
- 52-week range
- $68.77 $148.30
The short version
Where ZTS stands today, in four lines, and what CleaRank Financial AI makes of it.
ZTS at a glance
Zoetis Inc. (ZTS): Buy, 61/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($73.98 and $95.87).
- Earnings ZTS beat estimates in 7 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $2.7M and bought $886K over the last 18 months.
- Valuation P/E of 12.7 against 31.9 for the Healthcare sector: a discount to peers (-60%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Zoetis Inc. (ZTS) Buy, with a model score of 61/100.
Momentum lifts the score most: the 14-day RSI of 69.4 is in the bullish zone and the MACD line is positive. The trend holds it back most: the price is 17.22% below its 200-day average, and the 50-day average is 22.83% below the 200-day. The 50-day average stands at $73.98 and the 200-day at $95.87. Over the past year the price fell 44.60%.
Only on CleaRank
Figures we compute ourselves from ZTS's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $79.36 is 7.3% above the 50-day simple moving average of $73.98.Price above its 200-day average ›
The price is 17.2% below the 200-day simple moving average of $95.87.50-day average above the 200-day ›
The 50-day average ($73.98) is 22.8% below the 200-day average ($95.87), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 13% of its 52-week range, between $68.77 and $148.30.
ZTS share price
Pick a period: each tab shows how far ZTS has moved over it, to the last close.
Today's trading
Where ZTS sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 12.74 is 60.1% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 3.40 is 0.1% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $2.6B on revenue of $9.5B, a net margin of 27.7%.Beat estimates in most recent reports ›
ZTS beat the EPS estimate in 7 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 2.63%, or $2.09 a share a year.
Key statistics
The headline figures for ZTS.
As of October 17, 2026, ZTS trades at $79.36, with a market value of $32.80B, a P/E ratio of 12.74 and a dividend yield of 2.63%.
What the numbers say
CleaRank Financial AI's reading of ZTS's valuation, growth and risks.
ZTS trades at 12.74 times trailing earnings, and the P/E is 60.1% below the Healthcare sector median P/E of 31.9. The peer comparison on this page places it at a discount to peers. Measured against sales, the P/S of 3.40 sits level with the sector median of 3.4. Its market value stands at $32.8B, and trailing earnings come to $6.16 a share.
In the latest year revenue fell 0.20%, 8.3 percentage points slower than the sector median of 8.1%. The business earns a net margin of 27.69% and an operating margin of 40.72% and a return on equity of 64.91%, above the sector median of 7.3%. Debt-to-equity of 2.94 and a trailing dividend yield of 2.63% ($2.09 a share a year) round out the fundamentals.
EPS of $1.87 in the August 6, 2026 report beat the $1.85 that analysts expected, a margin of 1.08%. Even so, the stock fell 5.97% in the following session.
ZTS beat the EPS estimate in 7 of its last 8 reports, though the stock still fell in the first session after 3 of those 7 beats. The largest of the earlier reactions came after the May 7, 2026 report, which missed the estimate by 5.56% while the stock fell 5.13%. Analysts' average EPS estimate for this fiscal year is $6.21, which would be a decline of 3.1%, and $6.54 for next year (growth of 5.4%).
ZTS is best approached with day-to-day swings in mind, since its average session move is 1.59%. The stock is also 46.49% below its 52-week high of $148.30.
ZTS against the Healthcare sector
How ZTS compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: ZTS trades at a notable discount to sector peers (-60%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 6, 2025, ZTS has lost 47.1% against a gain of 31.4% for XLV.
Performance against XLV
ZTS and the Healthcare sector fund over the same days.
Revenue and earnings
How much ZTS sells, and how much of it becomes profit.
Revenue growth: Revenue grew 2.3% in FY2025 to $9.5B, from $9.3B a year earlier.
Profit margin: The net margin was 28.2% in FY2025, up from 27.0% the year before.
Profitable: ZTS earned $2.7B in FY2025.
Earnings reality check
Did ZTS beat what analysts expected, and how did the stock react?
Earnings record: ZTS beat the analyst estimate in 7 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 6, 2026after close | $1.85 | $1.87 | +1.08% | -5.97% | -1.85% |
| May 7, 2026after close | $1.62 | $1.53 | -5.56% | -5.13% | -13.55% |
| Feb 12, 2026after close | $1.40 | $1.48 | +5.71% | +0.80% | +2.50% |
| Nov 4, 2025after close | $1.62 | $1.70 | +4.94% | -3.19% | -3.49% |
| Aug 5, 2025after close | $1.61 | $1.76 | +9.32% | +0.26% | +2.50% |
| May 6, 2025after close | $1.40 | $1.48 | +5.71% | +4.08% | +7.03% |
| Feb 13, 2025after close | $1.36 | $1.40 | +2.94% | -4.49% | -2.71% |
| Nov 4, 2024after close | $1.46 | $1.58 | +8.22% | +0.05% | +0.55% |
As of October 17, 2026, ZTS has beaten the analyst EPS estimate in 7 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on August 6, 2026, came in 1.08% above the estimate and the stock moved -5.97% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 69.4, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 69.4 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of ZTS
The score, the reasoning behind it, and what could move the price next.
ZTS trades between its two moving averages. At $79.36, the stock is 17.22% below its 200-day average of $95.87 but 7.27% above its 50-day average of $73.98. Sitting at 13% of its 52-week range, the price is 15.40% above the 52-week low of $68.77. The 50-day average is 22.83% below the 200-day, a sign that the recent recovery has not yet climbed to the longer-run averages.
Recent gains sit against a weaker longer record: the price rose 8.71% over the past month, rose 3.66% over the past three months and fell 44.60% over the past year. On momentum, the 14-day RSI reads 69.4, in the bullish zone, below the overbought line, with the MACD line positive. The price rose 1.20% in the last session on volume 29.3% above its average.
Earnings beat ›
The August 6, 2026 report beat the EPS estimate by 1.08%, and the share price fell 5.97% in the first session after it.
Source: Earnings report, August 6, 2026
Rating reaffirmed ›
TD Cowen kept its Buy rating on August 25, 2026.
Source: Analyst action, TD Cowen, August 25, 2026
- The two levels closest to the price matter most: the 200-day SMA at $95.87 overhead and the 20-day EMA at $74.01 underneath.
- A 14-day RSI of 69.4 falls in the bullish zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- In the first session after the August 6, 2026 report, ZTS shares dropped 5.97%. Over the last 8 reports, the company has beaten estimates in 7 of them.
ZTS is pointing in mixed directions. The price is above its 50-day average of $73.98 but under its 200-day average of $95.87. Closing above the 200-day would turn both signals up, while closing below the 50-day would turn both down. For now, the price sits above the 20-day EMA at $74.01 and below the 200-day SMA of $95.87, which lies overhead.
ZTS has an RSI in the bullish band, which backs the current direction while staying near the overbought threshold.
Technical indicators
Momentum and trend for ZTS, from its daily closes.
As of October 17, 2026, with ZTS at $79.36, its 14-day RSI is 69.4 (showing bullish momentum without being overbought), its 50-day simple moving average is $73.98 and its 200-day is $95.87.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ZTS moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, ZTS's 1-year correlation of daily returns is +0.26 with S&P 500 (SPY), +0.14 with Nasdaq 100 (QQQ), +0.07 with Bitcoin (BTC) and +0.01 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
8 of 17 analysts rate it a buy or strong buy, 9 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $89.50 is 12.8% above the price.More buy ratings than three months ago ›
8 of 17 rate it a buy now, against 11 of 20 three months ago.
ZTS Wall Street View
12-month price targets
The price, $79.36, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Maintains | Buy |
| Aug 20, 2026 | Stifel | Maintains | Hold |
| Aug 11, 2026 | Citigroup | Maintains | Buy |
| Aug 11, 2026 | BNP Paribas | Maintains | Outperform |
| Aug 10, 2026 | Piper Sandler | Maintains | Neutral |
| Aug 7, 2026 | UBS | Maintains | Neutral |
As of October 17, 2026, 17 Wall Street analysts cover ZTS: 8 rate it a buy or strong buy, 9 a hold and 0 a sell or strong sell. Their 12-month price targets range from $80.00 to $155.00, with a median of $89.50, 12.8% above the price of $79.36.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ZTS trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ZTS's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ZTS tends to move, against the market and on its own.
The long record
ZTS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.59% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 69.7%, from December 2021 to September 2026; the price is still 65.8% below that peak.Most 1-year holds ended higher ›
65% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $17,306, against $42,058 in the S&P 500 (SPY).
ZTS Drawdowns & Recovery
As of October 17, 2026, ZTS's worst peak-to-trough fall over the last 10 years with dividends reinvested was -69.7% (December 2021 to September 2026); it is still 65.8% below that peak, and 65% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ZTS in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ZTS trailed the S&P 500 over this period: $17,306 against $42,058.
A $10,000 investment in ZTS in October 2016 would be worth about $17,306 today with dividends reinvested, compared with about $42,058 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ZTS, and which have not.
Strongest month, July: an average of +3.77%, up in 8 of 10 years.
Weakest month, March: an average of -3.83%, up in 3 of 10 years.
This month, October: has averaged -1.17%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ZTS's strongest calendar month has been July (average +3.77%, up in 8 of 10 years) and its weakest March (average -3.83%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ZTS, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ZTS today could grow to about $17,206 by 2036 in the base case, with a 90th-percentile outcome near $53,120 and a 10th-percentile outcome around $5,573. The simulation models price only; at today's 2.63% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ZTS Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $98.60 for ZTS by 2030 in the base case, from $79.36 today (1.2x over 4 years). The 10th-percentile path ends near $48.33. These are outcomes of a Monte Carlo simulation run on ZTS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $58.66 | $83.79 | $120 | |
| 2028 | $53.43 | $88.46 | $146 | |
| 2029 | $50.37 | $93.39 | $173 | |
| 2030 | $48.33 | $98.60 | $201 | |
| 2031 | $46.91 | $104 | $231 |
Method: a lognormal simulation of ZTS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
ZTS insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $886K on the open market and sold $2.7M.
As of October 17, 2026, ZTS insiders reported 2 open-market sales worth $2.7M and 3 open-market purchases worth $886K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 7, 2026 | Amelio Frank A D
Director
|
Grant | 6.7K | - |
| Jun 10, 2026 | Michael B Mccallister
Director
|
Grant | 1.2K | - |
| May 21, 2026 | Mark Stetter
Director
|
Grant | 1.6K | - |
| May 20, 2026 | Louise M Parent
Director
|
Grant | 12.1K | - |
| May 13, 2026 | Paul M. Bisaro
Director
|
Buy | 2.0K | $151.8K |
| May 13, 2026 | Amelio Frank A D
Director
|
Buy | 6.7K | $501.3K |
| May 11, 2026 | Michael B Mccallister
Director
|
Buy | 3.0K | $233.3K |
| Apr 30, 2026 | Kevin Ph.d. Esch
Officer
|
Grant | 259 | - |
| Mar 31, 2026 | Keith Sarbaugh
Officer
|
Grant | 1.5K | - |
| Mar 9, 2026 | Gregory Norden
Director
|
Grant | 1.2K | - |
| Feb 19, 2026 | Nicholas Ashton
Officer
|
Grant | 750 | - |
| Feb 19, 2026 | Paul M. Bisaro
Director
|
Grant | 1.6K | - |
| Feb 19, 2026 | Jamie Brannan
Officer
|
Grant | 1.2K | - |
| Feb 19, 2026 | Vanessa Broadhurst
Director
|
Grant | 1.6K | - |
| Feb 19, 2026 | Amelio Frank A D
Director
|
Option | 1.6K | $206.1K |
| Feb 19, 2026 | Rimma Driscoll
Officer
|
Grant | 454 | - |
| Feb 19, 2026 | Kevin Ph.d. Esch
Officer
|
Grant | 102 | - |
| Feb 19, 2026 | Astorga Jeannette Ferran
Officer
|
Grant | 431 | - |
| Feb 19, 2026 | Julie Fuller
Officer
|
Grant | 750 | - |
| Feb 19, 2026 | Gavin D K Hattersley
Director
|
Grant | 1.6K | - |
| Feb 19, 2026 | Sanjay Khosla
Director
|
Option | 1.6K | $206.1K |
| Feb 19, 2026 | Roxanne Lagano
Officer
|
Grant | 750 | - |
| Feb 19, 2026 | Antoinette Renee Leatherberry
Director
|
Grant | 1.6K | - |
| Feb 19, 2026 | Michael B Mccallister
Director
|
Grant | 1.6K | - |
| Feb 19, 2026 | Gregory Norden
Director
|
Grant | 1.6K | - |
| Feb 19, 2026 | Louise M Parent
Director
|
Grant | 1.6K | - |
| Feb 19, 2026 | Kristin C Peck
Chief Executive Officer
|
Grant | 7.4K | - |
| Feb 19, 2026 | Willie M Reed
Director
|
Grant | 1.6K | - |
| Feb 19, 2026 | Keith Sarbaugh
Officer
|
Grant | 386 | - |
| Feb 17, 2026 | Kristin C Peck
Chief Executive Officer
|
Sell | 20.0K | $2.5M |
| Feb 17, 2026 | Kristin C Peck
Chief Executive Officer
|
Option | 20.0K | $836.6K |
| Feb 6, 2026 | Nicholas Ashton
Officer
|
Grant | 779 | - |
| Feb 6, 2026 | Jamie Brannan
Officer
|
Grant | 909 | - |
| Feb 6, 2026 | Rimma Driscoll
Officer
|
Grant | 414 | - |
| Feb 6, 2026 | Kevin Ph.d. Esch
Officer
|
Grant | 93 | - |
| Feb 6, 2026 | Astorga Jeannette Ferran
Officer
|
Grant | 424 | - |
| Feb 6, 2026 | Wetteny Joseph
Chief Financial Officer
|
Grant | 2.8K | - |
| Feb 6, 2026 | Roxanne Lagano
Officer
|
Grant | 1.1K | - |
| Feb 6, 2026 | Kristin C Peck
Chief Executive Officer
|
Grant | 11.8K | - |
| Feb 6, 2026 | Keith Sarbaugh
Officer
|
Grant | 119 | - |
| Sep 30, 2025 | Julie Fuller
Officer
|
Grant | 784 | - |
| Sep 15, 2025 | Roxanne Lagano
Officer
|
Grant | 700 | - |
| Jul 25, 2025 | Vanessa Broadhurst
Director
|
Grant | 1.4K | - |
| Jun 3, 2025 | Roxanne Lagano
Officer
|
Sell | 652 | $110.8K |
| May 21, 2025 | Robert W Scully
Director
|
Grant | 17.5K | - |
| May 20, 2025 | Michael B Mccallister
Director
|
Grant | 1.8K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.